Analysis of 23 trials from an Iranian biosimilar manufacturer reveals 180 issues including arithmetic violations and design flaws, proposing clinical trial engineering as a distinct manipulation pattern and urging EMA-level regulators to require individual participant data.
Title resolution pending
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
cs.DL 1years
2026 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
A clinical trial engineering firm
Analysis of 23 trials from an Iranian biosimilar manufacturer reveals 180 issues including arithmetic violations and design flaws, proposing clinical trial engineering as a distinct manipulation pattern and urging EMA-level regulators to require individual participant data.